Induced Pluripotent Stem Cells (iPSCs) in Developmental Toxicology

Easley, Charles A.

doi:10.1007/978-1-4939-9182-2_3

Cited by 7 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our StemPanTox system could allow a tailor-made chemical toxicity assessment for these cells to detect individual differences in toxic tolerance for different substances. Ideally, it also has the potential to reduce medical accidents if myiPS cells could be used to diagnosis whether a medication is toxic before receiving the treatment ( Easley, 2019 ; Kim et al . , 2019 ).…”

Section: Discussionmentioning

confidence: 99%

StemPanTox: A fast and wide-target drug assessment system for tailor-made safety evaluations using personalized iPS cells

et al. 2022

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

StemPanTox: A fast and wide-target drug assessment system for tailor-made safety evaluations using personalized iPS cells

et al. 2022

View full text Add to dashboard Cite

“…Our hiPST-GN system could allow a tailor-made chemical toxicity assessment for these cells to detect individual differences in toxic tolerance for different substances. Ideally, it also has the potential to reduce medical accidents if myiPS cells could be used to diagnosis whether a medication is toxic before receiving the treatment 17,23 . In general, by performing a battery of toxicity assessments using multiple iPS cell lines from individuals with various haplotypes, our system may contribute to reducing toxicity accidents often caused by a small number of test samples of limited genomic variances.…”

Section: Discussionmentioning

confidence: 99%

Prediction of broad chemical toxicities using induced pluripotent stem cells and gene networks by transfer learning from embryonic stem cell data

Yamane

Wada

Otsuki

et al. 2021

Preprint

View full text Add to dashboard Cite

SUMMARYThe assessment of toxic chemicals using animals has limited applicability to humans. Moreover, from the perspective of animal protection, effective alternatives are also desired. Previously, we developed a method that combines developmental toxicity testing based on undifferentiated human embryonic stem (ES) cells (KhES-3) and gene networks. We showed that ≥ 95% accurate predictions could be achieved for neurotoxins, genotoxic carcinogens, and non-genotoxic carcinogens. Here, we expanded this method to predict broad toxicities and predicted the toxicity of 24 chemicals in six categories (neurotoxins, cardiotoxins, hepatotoxins, nephrotoxins [glomerular nephrotoxins/tubular nephrotoxins], and non-genotoxic carcinogens) and achieved high prediction accuracy (AUC = 0.90–1.00) in all categories. Moreover, to develop a testing system with fewer ethical issues, we screened for an induced pluripotent stem (iPS) cell line on the basis of cytotoxic sensitivity and used this line to predict toxicity in the six categories based on the gene networks of iPS cells using transfer learning from the ES cell gene networks. We successfully predicted toxicities in four toxin categories (neurotoxins, hepatotoxins, glomerular nephrotoxins, and non-genotoxic carcinogens) at high accuracy (AUC = 0.82–0.99). These results demonstrate that the prediction of chemical toxicity is possible even with iPS cells by transfer learning once a gene expression database has been developed from an ES cell line. This method holds promise for tailor-made safety evaluations using individual iPS cells.

show abstract

“…Maintaining these enzymatic expression levels and drug metabolism in a more true-to-human model avoids the model deviation found in PDXs. These features have led to organoids being useful across specialties including cardiology [ 42 , 43 ], toxicology [ 44 ], bacterial pathogenesis, and most recently COVID-19 research [ 45 , 46 ].…”

Section: Patient-derived Organoidsmentioning

confidence: 99%

Patient Derived Ex-Vivo Cancer Models in Drug Development, Personalized Medicine, and Radiotherapy

Zitter

Chugh

Saha

2022

Cancers

View full text Add to dashboard Cite

The field of cancer research is famous for its incremental steps in improving therapy. The consistent but slow rate of improvement is greatly due to its meticulous use of consistent cancer biology models. However, as we enter an era of increasingly personalized cancer care, including chemo and radiotherapy, our cancer models must be equally able to be applied to all individuals. Patient-derived organoid (PDO) and organ-in-chip (OIC) models based on the micro-physiological bioengineered platform have already been considered key components for preclinical and translational studies. Accounting for patient variability is one of the greatest challenges in the crossover from preclinical development to clinical trials and patient derived organoids may offer a steppingstone between the two. In this review, we highlight how incorporating PDO’s and OIC’s into the development of cancer therapy promises to increase the efficiency of our therapeutics.

show abstract

Induced Pluripotent Stem Cells (iPSCs) in Developmental Toxicology

Cited by 7 publications

References 35 publications

StemPanTox: A fast and wide-target drug assessment system for tailor-made safety evaluations using personalized iPS cells

StemPanTox: A fast and wide-target drug assessment system for tailor-made safety evaluations using personalized iPS cells

Prediction of broad chemical toxicities using induced pluripotent stem cells and gene networks by transfer learning from embryonic stem cell data

Patient Derived Ex-Vivo Cancer Models in Drug Development, Personalized Medicine, and Radiotherapy

Contact Info

Product

Resources

About